Home |Register |Login |Company Information
Our Company
Order Publications
Advertisers
Customer Service
|Survey |Help
Search MPR Database:

The most widely used drug reference by clinicians
Therapeutic Categories Brand Generic Manufacturer News
Drug News
New Products
Resources
Alerts (Sponsored)
Clinical Charts
Prescribing Notes
Manufacturer Index
empr Download We've Got Answers

Drug News

September 5, 2008
  • Afluria flu vaccine now available
  • Cardene IV Ready-to-Use Bag launched
September 4, 2008
  • Fungal infection warning strengthened for TNF-blockers
September 3, 2008
  • Omnitrope Pen 10 approved for growth hormone deficiency
  • ► August 2008
    • FDA approves generic Razadyne
    • Teva announces Zanosar shortage
    • Aloxi capsules approved for chemotherapy-induced nausea and vomiting
    • Nplate approved for chronic ITP
    • FDA expands Vidaza MDS approval
    • FDA investigates Vytorin cancer risk
    • FDA clearance for TRUE2go and TRUEresult glucose meters
    • Xanodyne announces methadone injection shortage
    • Asmanex Twisthaler now available for pediatric asthma
    • Byetta linked to additional cases of pancreatitis
    • Xenazine approved for Huntington’s disease
    • Fusilev available for methotrexate rescue
    • Generic Inspra now available
    • Additional adverse reactions for Vivitrol
    • FDA approves Viread for hepatitis B
    • Increased rhabdomyolysis risk with simvastatin and amiodarone
    • Watson's fentanyl 75mcg/hr transdermal patches recalled
    • Wyeth announces Phospholine Iodide shortage
    • Elestrin now available from BioSante
    • Rowasa convenience kit launched
    • Zostrix Neuropathy Cream available
    • Cancidas gains pediatric indication
    • FDA approves 2008-2009 flu vaccines
    • Diovan HCT and Exforge now first-line for hypertension
    • FDA approves Cleviprex for hypertension
    • FluMist now available for flu prevention
    ► July 2008
    • Evista blister packs now available
    • Stavzor approved for bipolar disorder, seizure, and migraine treatment
    • Covidien launches generic Restoril
    • Mylan launches generic Sular ER
    • Updated box warning for abacavir treatments
    • Locoid lotion available for atopic dermatitis
    • Teva announces Proglycem drug shortage
    • Teva launches generic Lamictal tablets
    • Roxane recalls sodium polystyrene sulfonate suspension
    • Anemia reported with unapproved Avastin combination
    • FDA updates Avandia labeling
    • » Patanase available for seasonal allergies
    • Aloxi 0.075mg available
    • Baxter discontinues Revex injection
    • Eovist approved as contrast for hepatic MRI
    • Fluoroquinolones gain boxed warning
    • PrimaCare Advantage prenatal vitamins available
    • Anthelios 40 sunscreen now available
    • Zingo now available for topical analgesia
    • Aciphex approved for adolescent GERD
    • FDA approves Evolence as facial dermal filler
    • Generic Risperdal launched
    ► June 2008
    • Generic Marinol launched
    • OTC Refresh Eye Itch Relief launched
    • Concerta approved for adult ADHD
    • Aptivus oral solution approved for HIV
    • Durezol approved for eye surgery recovery
    • Kinrix pediatric vaccine approved
    • Lexiscan launched for stress testing
    • PrandiMet approved for diabetes
    • Pentacel pediatric vaccine approved
    • Velcade approved for untreated multiple myeloma
    • Avodart combination approved for symptomatic BPH
    • Arkray launches Glucocard X-Meter monitor
    • Conventional antipsychotics get boxed warning
    • Spectrum to launch Fusilev injection
    • Trivaris approved for ocular inflammation
    • Ethex recalls additional morphine tablets
    • FDA approves Cymbalta for fibromyalgia
    • Requip XL approved for Parkinson’s
    • Ethex recalls morphine tablets
    • Cancer warning for Regranex
    • Entereg launched for GI surgical recovery
    • Shire recalls Daytrana patches
    • King discontinues Cortisporin otic suspension
    • Cortisporin ophthalmic suspension discontinued
    • FDA investigates pediatric cancer risk with TNF-blockers
    • King discontinues Kemadrin tablets
    • Reclast approved for fracture prevention
    • King discontinues Intal nebulizer solution
    • CFC-propelled inhalers to be discontinued
    ► May 2008
    • FDA approves two breast cancer regimens
    • FDA proposes revisions to pregnancy and breastfeeding drug labeling
    • Amitiza 8mcg capsules available
    • Additional Recothrom vial size approved
    • Barrier Therapeutics to launch Xolegel Duo
    • Generic Sarafem available
    • Entereg approved for GI surgical recovery
    • Ferralet 90 available for anemia treatment
    • Medicis recalls Solodyn
    • Additional Prezista tablet strength available
    • FDA issues CellCept and Myfortic pregnancy alert
    • Reformulated Leukine now available
    • CDC recommends shingle vaccination for elderly
    • Trasylol withdrawn from market
    • FDA approves Seroquel for bipolar maintenance
    • Generic Paxil CR launched
    • FDA approves Taclonex Scalp for psoriasis
    • Generic Yasmin approved
    • NovoSeven RT approved to control surgical bleeding
    • OraVerse approved for dental anesthetic recovery
    • Abilify gains expanded bipolar and schizophrenia indications
    • FDA approves Strattera for ADHD maintenance
    • Generic Dovonex scalp solution launched
    • King discontinues Tilade Inhaler
    • Metamucil Pink Lemonade available
    • Advair gains COPD indications
    ► April 2008
    • Amitiza gains IBS-C indication
    • FDA approves MixJect system for Trelstar
    • All lots of Digitek tablets recalled
    • OneTouch UltraLink Meter now available
    • FDA approves once-a-month Actonel for osteoporosis
    • Relistor approved for OIC
    • Suprax tablets now available
    • FDA approves Aplenzin for depression treatment
    • Vyvanse approved for adult ADHD
    • FDA approves Cimzia for Crohn’s disease
    • Tums QuikPak now available
    • FDA approves Anthelios 40 sunscreen
    • Omnaris available for allergy treatment
    • FDA approves Treximet for migraine treatment
    • Patanase approved for seasonal allergies
    • Abbott launches FreeStyle Freedom Lite monitor
    • Evamist now available for hot flash treatment
    • Luvox CR now available
    • FDA investigates CellCept and Myfortic PML risk
    • Lexiscan approved for MPI testing
    • Geocillin discontinued
    • Lung cancer warning for Exubera
    • Orencia gains JIA indication
    • More Heparin recalled
    • Rotarix vaccine approved for rotavirus prevention
    • Zelnorm treatment IND discontinued
    • Neuropsychiatric warning added to Relenza label
    • Neupro patches recalled
    ► March 2008
    • FDA evaluates Regranex cancer risk
    • FDA investigates suicide risk in Singulair users
    • FDA reviews MI risk in Videx, Ziagen users
    • Pedia-Lax line of products available
    • Revised dosing for Pegintron/Rebetol
    • Heparin Injection Solution recalled
    • Treanda approved for CLL
    • FDA reviews stroke risk in Spiriva users
    • NovoLog for CSII approved for pediatric use
    • Updated labeling for Enbrel
    • FDA approves additional Daptacel dose
    • Granisol oral solution now available
    • Hepatitis warning added to Prezista label
    • FDA issues Tussionex alert
    • Liquadd approved for ADHD
    • Levoleucovorin approved
    • More ESA labeling changes
    • Anestafoam launched for topical pain relief
    • Genzyme launches Renvela
    • FDA issues Tamiflu warning
    • Additional strengths of Opana ER approved
    • Additional strengths of OxyContin available
    • Aloxi gains indication
    • Enlon and Enlon-Plus injection discontinued
    • Pristiq approved for MDD
    ► February 2008
    • Abilify gains pediatric indication
    • Arcalyst approved for CAPS
    • FDA issues advisory for Spiriva and Foradil
    • Luvox CR approved for OCD and SAD
    • Tenormin injection discontinued
    • Teslac tablets discontinued
    • Canasa Pac launched for ulcerative proctitis
    • FDA issues Tysabri warning
    • Nexium approved for pediatric GERD
    • Salonpas pain relief patch approved
    • Avastin receives breast cancer approval
    • Sciele to launch Allegra ODT
    • Atralin gel available for acne
    • Humira gains indication
    • Xyntha approved for hemophilia A
    • Critical Therapeutics discontinues Zyflo
    • Fenoglide launched for cholesterol treatment
    • Additional fentanyl patches recalled
    • Additional Xyzal formulation approved
    • FDA approves Simcor for cholesterol treatment
    • King launches Altace tablets
    • KwikPen for Humalog and Humalog Mix available
    • Renova 60g tube available
    • Fentanyl 25mcg/hr transdermal patches recalled
    • Generic Pepcid Complete approved
    • Baxter suspends multi-dose heparin production
    • Icy Hot Heat Therapy recalled
    • Humatin capsules discontinued
    • FDA takes action against unapproved injectable colchicine products
    • Duricef oral suspension to be discontinued
    • Generic Fosamax launched
    • Tikosyn shortage resolved
    • Psorent launched for psoriasis
    • Asmanex Twisthaler approved for pediatric asthma
    • FDA warns of suicide risk with antiepileptics
    ► January 2008
    • Emend for injection now available
    • FDA reviews Vytorin and Zetia
    • Accretropin approved for pediatric growth failure
    • Moxatag, an extended-release formulation of amoxicillin approved
    • Bayer launches special access program for Leukine
    • Flector Patch available for pain relief
    • Flo-Pred approved for asthma
    • Humira gains psoriasis indication
    • More indications for Mycamine
    • Welchol gains diabetes indication
    • Additional warnings for Ortho Evra
    • Baxter recalls heparin
    • Intelence approved for HIV treatment
    • Tekturna HCT approved for hypertension
    • Tikosyn 0.25mg and 0.5mg shortage
    • Updated labeling for OTC Claritin
    • Additional warnings for Chantix
    • Recothrom approved to control surgical bleeding
    • FDA warning on children's OTC cough and cold medicines
    • Alvesco approved for asthma
    • Tysabri gains Crohn's disease indication
    • Aveeno launches eczema care product line
    • High purity Thrombin-JMI approved
    • Expanded indication for Evicel
    • Desonate TwinPack available for atopic dermatitis
    • Once-daily Cialis approved
    • Bisphosphonate safety alert
    • SymlinPen now available
    • Additional ESA safety information
    • Generic Kytril approved
    • Additional strengths of Vyvanse approved
    • FDA approves Sular reformulation
    • Luvox returns with OCD indication
    • Higher strength Glumetza tablets approved
    ► December 2007
    • Contour TS Test Strip Recalled
    • Voluven approved for Serious Blood Volume Loss
    • FDA updates fentanyl transdermal warning
    • Lexxel tablets to be discontinued
    • Viadur implants discontinued
    • FDA updates Nonoxynol 9 warning
    • Gelfoam Plus Hemostasis Kit approved to control surgical bleeding
    • Mederma Cream + SPF 30 available
    • Ranexa labeling updated
    • Bystolic approved for hypertension
    • Thyrogen gains thyroid cancer ablation indication
    • Kuvan approved for treating PKU
    • Veregen ointment approved
    • Duet DHA and Duet DHAec available for prenatal supplementation
    • FDA safety alert on carbamazepine
    • PedvaxHIB and COMVAX vaccines recalled
    • FDA concludes Prilosec and Nexium safety review
    • HalfLytely Bowel Prep Kit reformulated
    • Kytril oral solution discontinued
    • Similac launches nipple-ready bottles of infant formula
    • Desmopressin gains warning, loses indication
    • Diovan gains pediatric indication
    • Triesence approved for eye surgery
    ► November 2007
    • Bumex 0.5mg, 2mg tablets discontinued
    • Cymbalta OK'd for maintenance treatment of major depressive disorder
    • Roferon-A discontinued
    • Safety alert for Myfortic
    • Rosula CLK available
    • Unit-dose, preservative-free Tetanus Diphtheria vaccine approved
    • Abilify approved as adjunctive treatment for major depression
    • CitraNatal prenatal vitamins available for women
    • Safety alert for Chantix
    • Avalide approved as initial therapy for hypertension
    • FDA continues ongoing safety review of Cefepime
    • Nexavar approved for liver cancer
    • Zyrtec OTC approved for treating allergies
    • Expanded indication for Seroquel XR
    • Protonix for Delayed-Release Oral Suspension approved
    • Mircera approved for treating anemia in chronic renal failure patients
    • Natelle Plus DHA available for women
    • Cloderm Pump available to treat inflammation and pruritus
    • Fasprin, a no-swallow aspirin tablet available
    • Stronger boxed warning for Avandia
    • Lower-strength Kaletra tablets approved for pediatric patients
    • Procanbid tablets discontinued
    • Zyrtec-D approved for OTC use
    • Crestor gains indication
    • Sprycel labeling update
    • FDA approval of easypod, for use with Saizen
    • FDA strengthens labeling for erythropoiesis-stimulating agents
    • Prometheus to acquire Lotronex
    • Abilify approved for use in adolescents with schizophrenia
    • Marketing suspended for Trasylol
    • Combigan for treating ocular hypertension and glaucoma
    • Coraz Lotion available for treating seborrheic dermatitis
    • Mirapex 0.75mg tablet strength available
    • Pulmicort Respules 1mg ampules available
    • Zytopic Cream available for treating atopic dermatitis
    ► October 2007
    • CellCept use associated with pregnancy loss and congenital malformations
    • Generic Mirapex available
    • Tasigna approved for CML patients
    • Tilia Fe now available
    • TriLegest Fe available
    • Additional warnings for Provigil
    • Aleve-D available for multiple sinus and pain symptoms
    • Renvela approved as a phosphate binder
    • Updated storage conditions for Humate-P
    • Voltaren topical gel 1% for osteoarthritis
    • Expanded labeling for Januvia
    • Menactra OK'd for children 2-10 years of age
    • Potential risk of hearing loss with erectile dysfunction drugs
    • Pfizer discontinues Exubera
    • Epirubicin hydrochloride injection approved in four dosage forms
    • Ixempra approved for advanced breast cancer
    • Lexiva dosing update
    • Safety alert for Byetta
    • Sporanox injection discontinued
    • Doribax approved for complicated intra-abdominal and complicated urinary tract infections
    • Expanded labeling for Velcade
    • Hycamtin capsules approved for small cell lung cancer
    • Isentress tablets approved for HIV infection
    • Amrix available for muscle spasm
    • More Infant's Cough and Cold medications withdrawn
    • Agenerase Oral Solution and 50mg capsules discontinued
    • Generic Trileptal tablets approved
    • Infants' cough and cold products withdrawn from market
    • Generic Actonel tablets approved for marketing
    • Zyprexa and Symbyax labels updated
    • Updated labeling for Erbitux
    • Delsym available in grape-flavor
    • Lamisil Oral Granules for children with tinea capitis
    • Symlin pen-injector devices approved
    • Taxotere approved for treating head and neck carcinoma

Patanase available for seasonal allergies

Date Posted: July 10, 2008

Patanase (olopatadine HCl nasal spray, from Alcon), an H1-receptor antagonist, is now available for the relief of seasonal allergic rhinitis in patients ≥12 years of age.

For more information call (800) TO-ALCON or visit visit www.patanase.com.

From Haymarket Media, Inc. the Publishers of:
Monthly Prescribing Reference Nurse Practitioners' Prescribing Reference Physician Assistants' Prescribing Reference
Cortlandt Forum McKnight's Long-Term Care News Renal & Urology News The Clinical Advisor JAAPA McKnight's Assisted Living
HonCode
© Copyright 2008 | All Rights Reserved. | Disclaimer | Privacy Policy | Site Map | Print Subscription Questions | Online Acct. Help | Subscribe

Online CME
Haymarket Publishing